Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Thymidylate Synthase. Found 4 abstracts

Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Current treatment options in oncology. 2007 Oct;8(5):339-51.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr;91(7):1256-63.
O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Thymidylate Synthase

Thymidylate Synthase Aged Adult Female Male metabolism Predictive Value of Tests antagonists & inhibitors drug therapy US Gov't Support-PHS adverse effects Middle Age Thymidine Phosphorylase Antineoplastic Combined Chemotherapy Protocols therapeutic use Enzyme Inhibitors Biological Tumor Markers Human 80 and over Aged Colorectal Neoplasms Fluorouracil Nausea Immunohistochemistry Guanylate Cyclase Proportional Hazards Models Logistic Models Endonucleases Indoles 951-77-9 (Deoxycytidine) Metabolic Clearance Rate Effects] Loss of Heterozygosity en [Enzymology] Non-US Gov't Support chemically induced DNA-Binding Proteins pa [Pathology] Reverse Transcriptase Polymerase Chain Reaction Dihydrouracil Dehydrogenase (NADP) genetics 51-21-8 (Fluorouracil) Peptide Receptors Treatment Outcome ae [Adverse EC 2-1-1-45 (Thymidylate Synthase) Fatigue Fever drug effects dt [Drug Therapy] analysis Alanine Transaminase Survival Analysis adverse Feasibility Studies Gene Expression Profiling EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) pharmacology Gastrointestinal Neoplasms Middle Aged Epidermal Growth Factor Receptor Neoplastic Gene Expression Regulation Neoplasms Oral Administration analogs & me [Metabolism] effects Antineoplastic Antimetabolites Enzymologic Gene Expression Regulation ad [Administration & Dosage] Prognosis Bilirubin 7689-03-4 (Camptothecin) derivatives 154361-50-9 (capecitabine) Intravenous Infusions EC 2-4-2-4 (Thymidine Phosphorylase) Biological) 0 (Tumor Markers Lactate Dehydrogenases Carcinoembryonic Antigen tu [Therapeutic Use] blood Uracil Camptothecin Disease Progression pharmacokinetics Disease-Free Survival Area Under Curve Neoplasm Circulating Cells aa [Analogs & Derivatives] Leucovorin Oxidoreductases Non-US Gov't Research Support Aspartate Aminotransferases Microsatellite Instability pathology Neoplasm Staging Deoxycytidine Vomiting 100286-90-6 (irinotecan) Carcinoma mortality administration & dosage
Last updated on Wednesday, February 05, 2020